StockData
VivoSim Labs, INC. logo

VivoSim Labs, INC. (VIVS) company profile

VIVSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$0.12−0.00 (-2.91%)

Close on Nov 17, 2026Market cap $383.64KP/E –Yield –

About VivoSim Labs

Biological Products, (No Diagnostic Substances), SIC 2836

VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company that provides drug and drug candidate testing using three-dimensional human tissue models of the liver and intestine. The company offers liver and intestinal toxicology insights and predictive screening through its new approach methodologies models, which are designed to forecast adverse effects and intestinal tolerability across various phases of drug development. Its primary customers include pharmaceutical and biotechnology companies seeking to evaluate therapeutic candidates and elucidate drug mechanisms of action.

The company conducts its operations from principal executive offices in San Diego, California. VivoSim Labs operates alongside its subsidiaries and maintains intellectual property rights spanning multiple international jurisdictions, including Australia, Canada, China, Japan, and several European nations. As of June 2026, the organization employed 15 individuals, including 9 full-time workers, supplemented by scientific and operational consultants.

Summary of the business section of VivoSim Labs's latest annual report, written by StockData.

Company profile

Company

Legal name
VivoSim Labs, INC.
Founded
2007
Headquarters
San Diego, CA
Address
11555 Sorrento Valley Road, Suite 100 92121
Phone
(858) 224-1000
Website
vivosim.ai
Employees
15, Mar 31, 2026
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
March 31
Auditor
Rosenberg Rich Baker Berman, P.A., Somerset, New Jersey

Stock & identifiers

Ticker
VIVS
Former tickers
ONVO until Apr 24, 2025
Exchange
Nasdaq
IPO date
Feb 14, 2012
Shares outstanding
15M, Aug 10, 2026
Public float
$7.54M, Sep 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-12 reverse, Mar 21, 2025; 1-for-20 reverse, Aug 19, 2020
SEC CIK
1497253
CUSIP
68620A302
ISIN
US68620A3023
FIGI
BBG001M8GFD0
Share class FIGI
BBG001V10TP9
EIN
27-1488943

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Keith MurphyEXECUTIVE CHAIRMAN, Director6,094,968
Tony Serge LialinChief Commercial Officer10,000
Amar Akhtar SethiChief Scientific Officer–
Norm StaskeySee Remarks–
David GobelDirector15,000
Douglas Jay CohenDirector20,898
Adam K. SternDirector522,988
Alison Tjosvold MilhousDirector19,899

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2026$865.96K$779.74K$217.59K$1–
FY2025$1.17M$887.67K$135.90K$2–
FY2024$681.14K$595.61K$343.08K$11–
FY2023$621.45K$368.25K$390.86K$23–
FY2022$1.26M-$24.88K$779.56K$39–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2026

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsOtherTotalvs. prior year
Keith Murphy
Executive Chairman
$740.21K$73.50K$25.95K–$26.30K$865.96K-26%
Norman Staskey
Chief Financial Officer
$119.48K––––$119.48K+471%
Tony Lialin
Chief Commercial Officer
$221.54K$10.00K–$60.18K$6.24K$297.96K–
Amar Sethi
Chief Scientific Officer
$117.69K$15.00K–$99.72K$2.91K$235.33K–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of June 1, 2026, we had 15 employees, of which 9 are full-time.”

Corporate history

Events identified from SEC filings

DateEventDetails
Aug 21, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 24, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 29, 2026Late filingNotification of late filing
Apr 23, 2025Name changeName changed from ORGANOVO HOLDINGS, INC. to VivoSim Labs, INC.
Mar 26, 2025Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Feb 25, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 14, 2025Late filingNotification of late filing
Jan 17, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 24, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 5, 2023Auditor changeChange in certifying accountant (8-K Item 4.01)
Jul 24, 2023Auditor changeChange in certifying accountant (8-K Item 4.01)
Jun 29, 2023Late filingNotification of late filing
Sep 3, 2020Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 30, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 23, 2019MergerRegistration of securities for a merger or exchange offer (S-4)
Jun 28, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 5, 2016DelistingNotice of delisting from exchange (Form 25)
Jul 26, 2016ListingRegistration of securities on an exchange (Form 8-A)
Jul 26, 2016Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 9, 2013ListingRegistration of securities on an exchange (Form 8-A)
May 11, 2012Auditor changeChange in certifying accountant (8-K Item 4.01)
May 11, 2012Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Mar 30, 2012Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Mar 30, 2012Auditor changeChange in certifying accountant (8-K Item 4.01)
Feb 13, 2012Auditor changeChange in certifying accountant (8-K Item 4.01)
Feb 13, 2012Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 31, 2011Name changeName changed from REAL ESTATE RESTORATION & RENTAL, INC. to ORGANOVO HOLDINGS, INC.
Sep 28, 2011Late filingNotification of late filing

See a number that looks wrong?